RESEARCH-USE BIOSIMILAR ANTIBODY

Pinatuzumab

Antibody-drug conjugate · IgG1

SIGLEC2IgG1RUO

Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

TARGETSIGLEC2
YAntibody-drug conjugate
CATALOGSC-BS-270
CATALOG NUMBERSC-BS-270
MOLECULAR WEIGHTApprox. 146.69 kDa
PRODUCT FORMATAntibody-drug conjugate

A research-use configuration for comparative antibody studies

Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Pinatuzumab is a recombinant research-use antibody directed against SIGLEC2.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Pinatuzumab | StellaCyte